Brigitte Petesch-Pan

Brest, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Reply to the Correspondence: "Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses".

Reply to the Correspondence: "Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses".

Journal: Seminars in thrombosis and hemostasis

Published: July 23, 2026

Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?

Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?

Journal: Research and practice in thrombosis and haemostasis

Published: April 26, 2026

Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa.

Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa.

Journal: Blood advances

Published: March 13, 2026

Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study.

Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study.

Journal: Seminars in thrombosis and hemostasis

Published: January 13, 2026

Direct oral anticoagulants in the postpartum period: a report of real-life experience in the Hemorrhages and Thromboembolic Venous Disease of the Postpartum cohort study.

Direct oral anticoagulants in the postpartum period: a report of real-life experience in the Hemorrhages and Thromboembolic Venous Disease of the Postpartum cohort study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 31, 2025

Health-related quality of life in adults with von Willebrand disease: results of the French real-life Willebrand study on health-related quality of life.

Health-related quality of life in adults with von Willebrand disease: results of the French real-life Willebrand study on health-related quality of life.

Journal: Research and practice in thrombosis and haemostasis

Published: December 12, 2025

Epidemiology of venous thromboembolism during pregnancy and postpartum: results from the French prospective multicenter HEMOrrhage and venous THromboEmbolism in PostPartum study.

Epidemiology of venous thromboembolism during pregnancy and postpartum: results from the French prospective multicenter HEMOrrhage and venous THromboEmbolism in PostPartum study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: September 19, 2025

Venous and Arterial Thrombo-Embolic Events in Patients With von Willebrand Disease From Western France: The TWIGO Study.

Venous and Arterial Thrombo-Embolic Events in Patients With von Willebrand Disease From Western France: The TWIGO Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 13, 2025

Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.

Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.

Journal: British journal of haematology

Published: July 04, 2025

Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.

Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.

Journal: Annals of hematology

Published: June 24, 2025

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms.

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms.

Journal: EJHaem

Published: May 07, 2025

F8 gene variants influence the response to desmopressin in hemophilia A carriers.

F8 gene variants influence the response to desmopressin in hemophilia A carriers.

Journal: Blood

Published: May 06, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026